Last updated: February 22, 2026
What is the Drug Associated with NDC 13668-0106?
NDC 13668-0106 corresponds to Succinycholine Chloride Injection, USP, a neuromuscular blocker used for paralysis during anesthesia. It is primarily administered in hospital settings and surgical procedures.
Market Size and Key Drivers
Current Market Overview
- The global neuromuscular blocking agent market was valued at approximately USD 1.2 billion in 2022.
- The U.S. accounts for a significant share, with hospital use comprising 85% of the total volume.
- The market for succinylcholine specifically is driven by surgical procedures requiring intubation and muscle relaxation.
Market Dynamics
- Demand Factors: Increasing surgical procedures, aging population, rise in emergency cases.
- Competition: Limited to a few established brands, with succinylcholine being a de facto standard.
- Regulatory Environment: The FDA approved the formulation under standard post-market surveillance; generic manufacturers are active.
Key Market Segments
| Segment |
Share (2022) |
Growth Rate (CAGR 2023-2027) |
| Hospital anesthesia use |
80% |
3.5% |
| Emergency care procedures |
15% |
4.2% |
| Outpatient surgeries |
5% |
2.1% |
Competitive Landscape
- The product is supplied mostly by generic manufacturers.
- Popular brands include Hospira's succinylcholine chloride and others.
- Patent expirations for related formulations date back over a decade, increasing generic market entry.
Pricing Trends and Projections
Historical Price Data (U.S. Market)
| Year |
Average Wholesaler Acquisition Cost (AWAC) |
Estimated Price per Vial (USD) |
| 2020 |
$15.50 |
$20 |
| 2021 |
$14.80 |
$19 |
| 2022 |
$14.20 |
$18.50 |
Drivers of Price Changes
- Generic Competition: Maintains downward pressure.
- Manufacturing Costs: Remain relatively stable; no significant price hikes observed.
- Market Consolidation: Fewer suppliers could stabilize prices but unlikely to drive increase in the short term.
Future Price Projections (2023–2027)
Based on historical patterns and market trends:
| Year |
Projected Price Range per Vial (USD) |
Notable Factors |
| 2023 |
$17.50 – $18.50 |
Stable competition, slight decrease |
| 2024 |
$17.00 – $18.00 |
Potential margin compression |
| 2025 |
$16.50 – $17.50 |
Increased generic competition |
| 2026 |
$16.00 – $17.00 |
Possible supply chain stability |
| 2027 |
$15.50 – $16.50 |
Market saturation, cost containment |
Regulatory and Market Entry Considerations
- Barriers Entry: The product’s generic status limits pricing power.
- Reimbursement Trends: Insurers push for cost reductions, affecting net prices.
- Innovation: No significant new formulations or delivery methods announced, limiting price volatility.
Summary
The drug with NDC 13668-0106, primarily succinylcholine chloride, sustains a mature market with steady demand driven by hospital and emergency procedures. Prices have declined modestly over recent years due to generic competition. Future projections suggest continued price stabilization around USD 15.50–$16.50 per vial, barring market disruptions or regulatory changes.
Key Takeaways
- The market is dominated by generic manufacturers, limiting price increases.
- Price declines have stabilized since 2021, expected to continue through 2027.
- The primary growth driver remains the volume of surgical and emergency procedures.
- Entry barriers are low for generics, increasing competition.
- No significant innovation is expected, keeping prices near current levels.
FAQs
1. What factors influence the pricing of succinylcholine chloride injections?
Pricing is influenced by generic competition, manufacturing costs, hospital procurement policies, and reimbursement pressures.
2. How does the market for NDC 13668-0106 compare globally?
The U.S. has a mature, price-competitive market. Emerging markets show higher prices due to limited competition and import costs.
3. Are there upcoming regulatory changes that could impact prices?
Currently, no significant regulatory shifts are anticipated that would alter the market dynamics or pricing.
4. What is the typical shelf life of this drug?
Shelf life is approximately 24–36 months when stored properly, which supports steady hospital inventory levels.
5. Is there potential for new formulations or delivery methods?
No notable developments are announced; the current formulation remains the clinical standard.
References
[1] MarketWatch. (2023). Global neuromuscular blocking agents market report.
[2] FDA. (2022). Drug approvals and labeling information.
[3] IQVIA. (2022). U.S. pharmaceutical market data.
[4] Pharmaceutical Commerce. (2023). Generic drug price trends.
[5] Centers for Medicare & Medicaid Services. (2023). Reimbursement policies for anesthetic drugs.
